Profile data is unavailable for this security.
About the company
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products include therapeutic and preventive agents, sold by prescription, for the treatment of human disorders. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3, an inhibitory canonical Notch ligand. Its lead candidate, Restoret, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway.
- Revenue in USD (TTM)62.48bn
- Net income in USD13.74bn
- Incorporated1970
- Employees72.00k
- LocationMerck & Co Inc126 East Lincoln AvenueRAHWAY 07065United StatesUSA
- Phone+1 (908) 740-4000
- Fax+1 (908) 423-1987
- Websitehttps://www.merck.com/
Mergers & acquisitions
| Acquired company | MRK:NYQ since announced | Transaction value |
|---|---|---|
| Caraway Therapeutics Inc | 14.11% | 610.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Inc | 55.64bn | -2.59bn | 168.07bn | 88.00k | -- | 1.92 | 40.66 | 3.02 | -0.4643 | -0.4646 | 9.81 | 15.48 | 0.255 | 1.47 | 5.15 | 632,295.40 | -1.17 | 8.20 | -1.43 | 10.40 | 71.29 | 69.34 | -4.61 | 22.68 | 0.602 | -- | 0.4412 | 60.11 | -41.70 | 7.46 | -93.20 | -7.94 | 12.21 | 3.82 |
| Amgen Inc | 30.93bn | 3.13bn | 180.52bn | 26.70k | 57.83 | 30.46 | 22.00 | 5.84 | 5.81 | 5.81 | 57.47 | 11.03 | 0.3415 | 1.75 | 4.85 | 1,158,577.00 | 3.46 | 10.36 | 4.39 | 13.06 | 63.30 | 75.41 | 10.12 | 26.51 | 0.8928 | 1.59 | 0.9136 | 59.54 | 7.09 | 3.49 | 2.52 | -4.36 | 8.54 | 10.04 |
| Merck & Co Inc | 62.48bn | 13.74bn | 297.16bn | 72.00k | 21.75 | 6.82 | 16.65 | 4.76 | 5.39 | 5.39 | 24.66 | 17.19 | 0.5756 | 2.44 | 5.51 | 867,763.90 | 12.67 | 7.70 | 16.42 | 10.29 | 75.79 | 72.26 | 22.01 | 15.03 | 1.22 | 23.69 | 0.464 | 89.55 | 1.40 | 7.29 | -97.49 | -43.80 | 8.12 | 8.26 |
| AbbVie Inc | 55.00bn | 5.30bn | 342.00bn | 50.00k | 64.78 | 50.45 | 24.65 | 6.22 | 2.99 | 2.99 | 31.03 | 3.84 | 0.3967 | 4.43 | 4.74 | 1,100,000.00 | 3.86 | 6.55 | 5.27 | 8.40 | 66.65 | 69.74 | 9.73 | 16.46 | 0.7061 | 8.92 | 0.9119 | 111.46 | -6.44 | 10.65 | -59.09 | -3.44 | 4.02 | 10.52 |
| Johnson & Johnson | 86.58bn | 16.38bn | 396.76bn | 131.90k | 24.73 | 5.55 | 17.05 | 4.58 | 6.66 | 15.15 | 35.22 | 29.72 | 0.4645 | 2.11 | 5.32 | 656,376.10 | 8.79 | 8.93 | 12.44 | 11.96 | 69.43 | 68.17 | 18.92 | 18.86 | 0.8464 | 146.62 | 0.3671 | 71.25 | 6.46 | 0.8622 | -18.59 | -2.72 | 4.36 | 5.83 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 232.95m | 9.19% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 127.35m | 5.02% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 117.49m | 4.64% |
| Wellington Management Co. LLPas of 30 Jun 2024 | 69.30m | 2.73% |
| Geode Capital Management LLCas of 30 Jun 2024 | 57.02m | 2.25% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 43.07m | 1.70% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 33.81m | 1.33% |
| BlackRock Investment Management (UK) Ltd.as of 30 Jun 2024 | 25.07m | 0.99% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 24.64m | 0.97% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 21.14m | 0.83% |
